Key result
Proactive IL-6 and IL-1 inhibitors emerge as key strategies to prevent CAR T-cell cardiovascular and neurotoxicity.
Why the study?
Chimeric antigen receptor T-cell therapy causes immune-mediated toxicities leading to cardiovascular complications, driving a shift from reactive treatment toward proactive, cytokine-targeted strategies.
Contemporary management of CAR T-cell therapy toxicities is shifting towards proactive strategies, emphasizing early risk stratification and timely intervention with cytokine-directed therapies to prevent cardiovascular and neurotoxicity.
May warrant heightened CV monitoring during CAR-T therapy; leaves open prospective studies on targeted cytokine blockade.
Chimeric antigen receptor T-cell therapy has revolutionized the treatment of hematological malignancies but is associated with significant immune-mediated toxicities, particularly cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, driven by an exaggerated inflammatory response involving cytokines such as interleukin (IL)-6, IL-1, and tumor necrosis factor-alpha. These processes contribute to endothelial dysfunction and a spectrum of cardiovascular complications, including hypotension, arrhythmias, myocardial dysfunction, and heart failure. The underlying pathophysiology involves complex interactions between immune activation and vascular injury, often progressing rapidly and necessitating early recognition. Contemporary management is shifting from reactive treatment to proactive strategies, emphasizing early risk stratification using clinical parameters, biomarkers, and imaging, alongside timely intervention with cytokine-directed therapies such as IL-6 and IL-1 inhibitors. Integration of cardiology within multidisciplinary care teams is essential for optimizing outcomes through tailored monitoring and management of cardiovascular complications. As chimeric antigen receptor T-cell therapy expands to broader and higher-risk populations, including those with pre-existing cardiovascular disease, a structured cardio-oncology approach and further prospective research are critical to improving safety and long-term outcomes.
No takes yet. Share an insight, caveat, or question.
Thukral et al. (2026) conducted a review in Hematological malignancies undergoing Chimeric antigen receptor (CAR) T-cell therapy. Pre-emptive and prophylactic cytokine-targeted interventions (e.g., tocilizumab, anakinra) was evaluated. Proactive cytokine-directed therapies, including IL-6 and IL-1 inhibitors, are highlighted as critical strategies to prevent cardiovascular and neurotoxicity in patients receiving CAR T-cell therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: